The FDA approved the first of the new herbal medicines to be marketed in the United States, a combination of azaleas and fenugreek that can help people with hepatitis C. The new drugs, which were developed by GW Pharmaceuticals and GW Pharmaceutical Co., are available in a number of states.
The FDA also approved a second, approved drug that contains fenogrel and anastrozole.
These drugs are currently being tested for safety in the U.S. GW Pharmaceutical is the largest U.K. drugmaker.
The drugs are made by GW Pharma in the Netherlands.
“We’re delighted to be the first to introduce GW’s new hepatitis C treatment to the United Kingdom,” said Janna M. Friese, director of the U,K.
Department of Health and Social Care, in a statement.
The two new drugs are part of a $100 million expansion of the drug program for people who have HCV and are eligible for hepatitis C drugs.
“The U. K. Health Service has been clear that the current hepatitis C strategy is not sustainable and that there is a need to bring new treatments to the market in a more affordable, accessible, and more effective way,” said Frieser.
GW Pharma said it is also developing an oral anti-inflammatory drug that can be used as an adjuvant to an existing treatment and is in the early stages of development.
The company said it expects to release the oral drug in 2018.
A total of seven new hepatitis B drugs were approved in the past year, including one that has already begun to be used in patients.
As a result of the recent hepatitis C pandemic, the FDA also announced a $2.6 billion budget for the United Nations AIDS program.
The budget includes $4.7 billion for the Global Fund to Fight AIDS, Tuberculosis, Malaria and HIV.
The United Nations spends about $6 billion annually on AIDS and tuberculosis.
The Global Fund’s budget includes about $2 billion to support the development of the WHO’s global drug surveillance network.
Some of the other new drugs approved in 2018 include: Methuselah, an anastroglobulin derivative; Echinacea, an antioxidant; and Pisumaremia, a skin and hair-softening drug.
Last year, the U .
K. government announced a new $1.5 billion plan to address the pandemic.
The government will provide $1 billion for research and development of new drugs that will be sold through the drug company GW Pharmaceutical.
Other U. S. pharmaceutical companies have also received approvals from the FDA.
Last year, Pfizer, the maker of Adderall, received approval to sell its ADHD drug, a drug that has been shown to improve attention in children and adults with ADHD.
In 2016, AstraZeneca, maker of Zoloft, received an FDA approval for a cancer treatment.
The drug, called Pembrolizumab, has been tested in patients with multiple myeloma.
In 2019, Pfennig Pharmaceuticals received approval for the treatment of type 1 diabetes.
In 2018, Astellas Wyeth received a U.N. approval for its treatment of diabetes in patients over age 60.
In 2018, Wyeth, a U .
S. health care company, received a $1 million grant from the U of S. Department for International Development to develop a cancer drug.
The U.s. government also announced that it will provide a $5 million grant for Wyeth’s research into new treatment for cancer.
Finally, the government announced it will give Pfizer and Astra Zeneca a $7.6 million grant to continue to develop the treatment for patients with Type 1 diabetes in the developed world.